Recombinant human growth hormone improves the fat redistribution syndrome (lipodystrophy) in patients with HIV

AIDS

Volumn 13, Issue 15, 1999, Pages 2099-2103

  Wanke, Christine ^a,b   Gerrior, Jul ^a,b   Kantaros, Julie ^b   Coakley, Eoin ^b   Albrecht, Mary ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Body composition; Fat redistribution syndrome; Growth hormone; HIV; Lipodystrophy

Indexed keywords

CD4 ANTIGEN; HUMAN GROWTH HORMONE; VIRUS RNA;

ADULT; ANTHROPOMETRY; ARTICLE; BODY BUILD; BODY COMPOSITION; BODY MASS; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERGLYCEMIA; IMPEDANCE; LIPODYSTROPHY; LYMPHOCYTE COUNT; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SUBCUTANEOUS DRUG ADMINISTRATION;

ADULT; BODY COMPOSITION; FEMALE; GROWTH HORMONE; HIV INFECTIONS; HUMANS; LIPODYSTROPHY; MALE; PROSPECTIVE STUDIES;

EID: 0032712266     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199910220-00013     Document Type: Article

References (26)

1. Carr A, Samaras K, Burton S, Law M, Freund J, Chisolm DJ, Cooper DA. A syndrome of peripheral lipodystrophy, hyperlidemia and insulin resistance due to HIV protease inhibitors. AIDS 1998, 12:F51-F58.
2. Wong-Beringer A, Beringer P, Lovett MA. Hypertrophy of breasts in a patient treated with indinavir [letter]. Clin Infect Dis 1997, 25:937.
3. Striker R, Conlin D, Marz M, Wiviott L. Localized adipose tissue hypertrophy in patients receiving immunodeficiency virus protease inhibitors. Clin Infect Dis 1998, 27:218-220.
4. Lipsky, J. Abnormal fat accumulation in patients with HIV-1 infection. Lancet 1998, 351:847-848.
5. Miller KK, Daly PA, Sentochnik D, Doweiko J, Samore M, Basgoz NO, Grinspoons. Pseudo-Cushings syndrome in human immunodeficiency virus-infected patients. Clin Infect Dis 1998, 27:68-72.
6. Roth VR, Kravcik S, Angel JB. Development of cervical fat pads following therapy with human immunodeficiency virus type 1 protease inhibitors. Clin Infect Dis 1998; 27:65-70.
7. Dong K, Flynn MM, Dickinson BP, Rich JR, Tashima K, Flanigan TP, Carpenter CCJ. Changes in body habitus in HIV+ women after initiation of protease inhibitor therapy. 12th World AIDS Conference, Geneva, July 1998 (Abstract no. 12373].
8. Lo JC, Mulligan K, Tai VW, Algren H, Schambelan M. Buffalo hump in HIV infected patients on antiretroviral therapy. Lancet 1998, 351:867-870.
9. Wurtz, R. Buffalo hump in HIV. Lancet 1998, 351:1735-1736.
10. Schindler JT, Sponer KM, Decker CF. Buffalo humps associated with protease inhibitors [letter]. Ann Intern Med 1998, 129:164.
11. Mulligan K, Tai VW, Algren H, Chernoff DN, Lo JC, Schambelan M. Evidence of unique metabolic effects of protease inhibitors. 5th Conference on Retroviruses and Opportunistic Infections, 1998 [Abstract no. 414].
12. Sullivan AK, Feher MD, Nelson MR, Gazzard BG. Marked hypertriglyceridemia on ritonavir therapy [letter]. AIDS 1998; 12:1393-1394.
13. Walli RK, Hefort O, Michl CM, et al. Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1 infected patients. AIDS 1998; 12:F167-F173.
14. Carr A, Samaras K, Chisolm DJ, Cooper DA. Pathogenesis of HIV-1 protease inhibitor associated peripheral lipodystrophy, hyperlipidemia, and insulin resistance. Lancet 1998, 352:1881-1883.
15. Miller K, Jones E, Yanovski J, Shankar R, Feuerstein I, Falloon J. Visceral abdominal fat accumulation associated with use of indinavir. Lancet 1998, 351:871-875.
16. Engelson EE, Kotler DP, Tan XY, Agin D, Bashist B, Wang J, Heymsfield SB. Altered body fat distribution in HIV infections: regional body composition measurements by whole body MRI and DXA scans. 12th World AIDS Conference, Geneva, July 1998 [Abstract no. 32181).
17. Kotler DP, Rosenbaum KB, Wang RN, Pierson RN. Alterations in body fat distribution in HIV-infected men and women. 12th World AIDS Conference, Geneva, July 1998 [Abstract no. 32173].
18. Wanke CA. Epidemiological and clinical aspects of the metabolic complications of HIV infection: the fat redistribution syndrome. AIDS 1999; 13:1287-1293.
19. Hirsch M, Klibanski A. What price progress? Pseudo-Cushing's syndrome associated with antiretroviral therapy in patients with human immunodeficiency virus infection. Clin Infect Dis 1998, 27:73-75.
20. Torres R, Unger KW. Treatment of dorsocervical fat pads (buffalo hump) and truncal adiposity with Serostim (recombinant human growth hormone) in patients with AIDS maintained on HAART. 12th World AIDS Conference, Geneva, July 1998 [Abstract no. 32164].
21. Durnin JVGA, Wormersley J. Body fat assessed from total body density and its estimation from skinfold thickness: measurement of 481 men and women aged 16 to 72 years. Br J Nutr 1974, 32:77-96.
22. Callaway CW, Chumlea WC, Bouchard C, et al. Circumference, in anthropometric standardization reference manual. Lohman TC, Roche AF, Martovell R, editors. Champagne, IL: Human Kinetics Books; 1988.
23. Frisancho AR. New norms of upper limb fat and muscle areas for assessment for nutritional status. Am J Clin Nutr 1981, 34:2540-2545.
24. Pettit R, Muurahainen N, Falutz J, et al. HIV related truncal obesity: a comparison of physician and patient diagnosis. 6th Conference on Antiretroviral Therapy, Chicago, 1999 [Abstract no. 651].
25. Cuneo RC, Judd S, Wallace JD, et al. The Australian multicenter trial of GH treatment in GH-deficient adults. J Clin Endocrinol Metab 1998; 83:107-116.
26. Spiegelman D, Israel RC, Bouchard C, Willett WC. Abdominal fat mass, percent body fat, and body fat distribution: which is the real determinant of blood pressure and glucose. Am J Clin Nutr 1992; 55:1033-1044.